Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., . . . Konopleva, M. (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. American Society of Hematology.
Chicago-tyylinen lähdeviittausZeng, Zhihong, et al. Rapamycin Derivatives Reduce MTORC2 Signaling and Inhibit AKT Activation in AML. American Society of Hematology, 2007.
MLA-viiteZeng, Zhihong, et al. Rapamycin Derivatives Reduce MTORC2 Signaling and Inhibit AKT Activation in AML. American Society of Hematology, 2007.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.